Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
52-week randomized open-label study of Ixekizumab versus Adalimumab in biologic-naive psoriatic arthritis
2016-004585-25Phase 4Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ixekizumab in psoriatic arthritis (PsA) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Simultaneous achievement of ACR50 and PASI100. Started Apr 2017; status: completed.
02
Drugs
ixekizumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2016-004585-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004585-25.